Carbohydrate antigen (CA) 19-9 is a type of antigen released by pancreatic cancer cells. It can also be referred to as a tumor marker. The CA 19-9 Radioimmunoassay (RIA) is a blood test that measures the CA 19-9 level in the blood. There is no blood test to find or diagnose pancreatic cancer.
CA 19-9 assay values can assist in the differential diagnosis and monitoring of patients with pancreatic carcinoma (sensitivity 70% to 87%). 6-12 There is no correlation between tumor mass and the CA 19-9 assay values; however, patients with CA 19-9 serum levels …
The tumour marker CA19-9 is a sensitive marker for pancreatic, gastric and hepatobiliary malignancies. High CA 19-9 level indicates unresectable lesions and a poor prognosis. The objective of the study was to determine the significance and implications of elevated CA 19-9 levels in the serum. A one- …
The CA 19-9 marker is associated with cancers in the colon, stomach, and bile duct. Elevated levels of CA 19-9 may indicate advanced cancer in the pancreas, but it is also associated with noncancerous conditions, including gallstones, pancreatitis, cirrhosis of the liver, and cholecystitis.
CA19 : Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen. CA 19-9 may be elevated in patients with gastrointestinal malignancies such as cholangiocarcinoma, pancreatic cancer, or colon cancer. Benign conditions such as cirrhosis, cholestasis, and pancreatitis also result in elevated serum CA 19-9 concentrations but in these cases values usually are below 1,000 U/mL.
CA 19-9 does not cause cancer; rather, it is a protein that is produced by the tumour cells, making it useful as a tumour marker to follow the course of the cancer. CA 19-9 is elevated in most patients with advanced pancreatic cancer , but it may also be elevated in other cancers and diseases such as bowel cancer , lung cancer, gall bladder
CA 19-9: abbreviation for cancer antigen 19-9 antigen, a blood tumor marker for pancreatic, hepatobiliary and colorectal cancer. This tumor marker is used in diagnosis, evaluation of a patients response to treatment, and surveillance of the disease.
CA19-9 is a monoclonal antibody that was first discovered in the serum of patients with colon cancer. Since that time CA19-9 has been used as a tumor marker for a variety of cancers.
CA19 : Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen. CA 19-9 may be elevated in patients with gastrointestinal malignancies such as cholangiocarcinoma, pancreatic cancer, or colon cancer.
CA 19-9 (carbohydrate antigen 19-9 or cancer antigen 19-9) is a serum antigen (monosialoganglioside) that has increased diagnostic use in the management of several malignancies, mainly of hepatopancreaticobiliary origin.It is non-specific, however, and can rise in both malignant and non-malignant conditions. Elevated serum CA 19-9. Elevation of serum CA 19-9 has been associated with …
This test looks for the antigen called cancer antigen 19-9 (CA 19-9) in your blood. Antigens are substances that stimulate your bodys immune system. Some types of cancer cells send CA 19-9 into the blood, where it can be measured with this test. A high amount of CA 19-9 is most often caused by pancreatic cancer.
CA 19-9 - A large percentage of patients with gastrointestinal tumors (such as pancreatic, liver, gastric, colorectal tumors) and some other malignancies have been shown to have elevated serum CA 19-9 levels. Serum CA 19-9 levels may be useful for monitoring disease activity or predicting relapse following treatment. CA 19-9 should not be used as a screening test.